{{expert needed|1=Pharmacology|date=August 2014}}
{{Drugbox
| verifiedrevid = 470473060
| IUPAC_name = 4-amino-''N''-(5-methyl-1,3,4-thiadiazol-2-yl)- benzenesulfonamide
| image = Sulfamethizole.svg
| width = 250
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|sulfamethizole}}
| MedlinePlus = a682231
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 98–99%
| metabolism =  
| elimination_half-life = 3–8 hours
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 144-82-1
| ATC_prefix = B05
| ATC_suffix = CA04
| ATC_supplemental =  {{ATC|D06|BA04}} {{ATC|J01|EB02}} {{ATC|S01|AB01}} {{ATCvet|J01|EQ02}}
| PubChem = 5328
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00576
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5137
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 25W8454H16
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00870
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9331
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1191
<!--Chemical data-->
| C=9 | H=10 | N=4 | O=2 | S=2
| molecular_weight = 270.333 g/mol
| smiles = O=S(=O)(Nc1nnc(s1)C)c2ccc(N)cc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VACCAVUAMIDAGB-UHFFFAOYSA-N
}}
'''Sulfamethizole''' is a [[sulfonamide (medicine)|sulfonamide]] [[antibiotic]].

==References==
* {{cite journal |vauthors=Ratanajamit C, Skriver M, Nørgaard M, Jepsen P, Schønheyder H, Sørensen H | title = Adverse pregnancy outcome in users of sulfamethizole during pregnancy: a population-based observational study. | journal = J Antimicrob Chemother | volume = 52 | issue = 5 | pages = 837–41 | year = 2003 | pmid = 14519675 | doi = 10.1093/jac/dkg438}}
* {{cite journal |vauthors=Kerrn M, Frimodt-Møller N, Espersen F | title = Effects of Sulfamethizole and Amdinocillin against Escherichia coli Strains (with Various Susceptibilities) in an Ascending Urinary Tract Infection Mouse Model | journal = Antimicrob Agents Chemother | volume = 47 | issue = 3 | pages = 1002–9 | year = 2003 | pmid = 12604534 | doi = 10.1128/AAC.47.3.1002-1009.2003 | pmc = 149286}}
* {{cite journal |vauthors=Watanabe H, Hastings J | title = Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine | journal = Biochim Biophys Acta | volume = 1017 | issue = 3 | pages = 229–34 | year = 1990 | pmid = 2372557 | doi = 10.1016/0005-2728(90)90189-B}}

{{Antibiotics and chemotherapeutics for dermatological use}}
{{SulfonamideAntiBiotics}}

[[Category:Sulfonamide antibiotics]]
[[Category:Thiadiazoles]]


{{antibiotic-stub}}
{{blood-drug-stub}}
{{dermatologic-drug-stub}}